OBJECTIVE: To investigate the impact of adjuvant hepatic artery infusion (HAI) in relation to KRAS mutational status in patients with resected colorectal cancer liver metastases (CRLM). BACKGROUND: Patients with KRAS-mutated CRLM have worse outcomes after resection. Adjuvant HAI chemotherapy improves overall survival after liver resection. METHODS: Patients with resected CRLM treated at MSKCC with and without adjuvant HAI who had available KRAS status (wild-type, WT; mutated, MUT) were reviewed from a prospectively maintained institutional database. Correlations between KRAS status, adjuvant HAI, clinical factors, and outcomes were analyzed. Cox proportional hazard model was used to adjust for confounders. RESULTS: Between 1993 and 2012, 674 patients (418 KRAS-WT, 256 MUT) with a median follow up of 6.5 years after resection were evaluated. Fifty-four percent received adjuvant HAI. Tumor characteristics (synchronous disease, number of lesions, clinical-risk score, 2-stage hepatectomy) were significantly worse in the HAI group; however, there were more patients with resected extrahepatic metastases in the no-HAI group. In KRAS-WT tumors, 5-year survival was 78% for patients treated with HAI versus 57% for patients without HAI [hazard ratio (HR) 0.51, P < 0.001]. In KRAS-MUT tumors, 5-year survival was 59% for patients treated with HAI versus 40% for patients without HAI (HR 0.56, P < 0.001). On multivariate analysis, HAI remained associated with improved OS (HR 0.53, P < 0.002) independent of KRAS status and other clinicopathologic factors. CONCLUSION: Adjuvant HAI after resection of CRLM is independently associated with improved outcomes regardless of KRAS mutational status. Adjuvant HAI may mitigate the worse outcomes seen in patients with resectable KRAS-MUT CRLM.
OBJECTIVE: To investigate the impact of adjuvant hepatic artery infusion (HAI) in relation to KRAS mutational status in patients with resected colorectal cancer liver metastases (CRLM). BACKGROUND:Patients with KRAS-mutated CRLM have worse outcomes after resection. Adjuvant HAI chemotherapy improves overall survival after liver resection. METHODS:Patients with resected CRLM treated at MSKCC with and without adjuvant HAI who had available KRAS status (wild-type, WT; mutated, MUT) were reviewed from a prospectively maintained institutional database. Correlations between KRAS status, adjuvant HAI, clinical factors, and outcomes were analyzed. Cox proportional hazard model was used to adjust for confounders. RESULTS: Between 1993 and 2012, 674 patients (418 KRAS-WT, 256 MUT) with a median follow up of 6.5 years after resection were evaluated. Fifty-four percent received adjuvant HAI. Tumor characteristics (synchronous disease, number of lesions, clinical-risk score, 2-stage hepatectomy) were significantly worse in the HAI group; however, there were more patients with resected extrahepatic metastases in the no-HAI group. In KRAS-WT tumors, 5-year survival was 78% for patients treated with HAI versus 57% for patients without HAI [hazard ratio (HR) 0.51, P < 0.001]. In KRAS-MUT tumors, 5-year survival was 59% for patients treated with HAI versus 40% for patients without HAI (HR 0.56, P < 0.001). On multivariate analysis, HAI remained associated with improved OS (HR 0.53, P < 0.002) independent of KRAS status and other clinicopathologic factors. CONCLUSION: Adjuvant HAI after resection of CRLM is independently associated with improved outcomes regardless of KRAS mutational status. Adjuvant HAI may mitigate the worse outcomes seen in patients with resectable KRAS-MUT CRLM.
Authors: Hordur M Kolbeinsson; Randa Preihs; Alexandra Bengel; Sreenivasa Chandana; M Mura Assifi; Mathew H Chung; G Paul Wright Journal: J Gastrointest Oncol Date: 2022-02
Authors: Raja R Narayan; Jashodeep Datta; Debra A Goldman; Victoria G Aveson; Henry S Walch; Francisco Sanchez-Vega; Mithat Gönen; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; T Peter Kingham; Alice C Wei; Nikolaus Schultz; Nancy E Kemeny; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2022-07-27 Impact factor: 4.339
Authors: Florian E Buisman; Daniele Giardiello; Nancy E Kemeny; Ewout W Steyerberg; Diederik J Höppener; Boris Galjart; Pieter M H Nierop; Vinod P Balachandran; Andrea Cercek; Jeffrey A Drebin; Mithat Gönen; William R Jarnagin; T P Kingham; Peter B Vermeulen; Alice C Wei; Dirk J Grünhagen; Cornelis Verhoef; Micheal I D'Angelica; Bas Groot Koerkamp Journal: Eur J Cancer Date: 2022-04-14 Impact factor: 10.002
Authors: Florian E Buisman; Boris Galjart; Eric P van der Stok; Nancy E Kemeny; Vinod P Balachandran; Thomas Boerner; Andrea Cercek; Dirk J Grünhagen; William R Jarnagin; T Peter Kingham; Cornelis Verhoef; B Groot Koerkamp; Michael I D'Angelica Journal: HPB (Oxford) Date: 2019-12-27 Impact factor: 3.647
Authors: Raja R Narayan; Victoria G Aveson; Joanne F Chou; Henry S Walch; Francisco Sanchez-Vega; Gustavo Dos Santos Fernandes; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; William R Jarnagin; Alice C Wei; Andrea Cercek; Mithat Gönen; Nikolaus Schultz; T Peter Kingham Journal: J Surg Oncol Date: 2022-01-23 Impact factor: 2.885